Effect of 36 CYP2C9 variants found in the Chinese population on losartan metabolism in vitro

Xenobiotica

Volumn 44, Issue 3, 2014, Pages 270-275

  Wang, Yu Han ^a   Pan, Pei Pei ^b   Dai, Da Peng ^c   Wang, Shuang Hu ^b   Geng, Pei Wu ^b   Cai, Jian Ping ^c   Hu, Guo Xin ^b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

Allelic variant; Catalytic activity; CYP2C9; Losartan

Indexed keywords

ANALYSIS OF VARIANCE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GENETIC VARIATION; HUMANS; KINETICS; LOSARTAN; MICROSOMES;

EID: 84893696264     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.820007     Document Type: Article

References (24)

1. Bae JW, Choi CI, Kim MJ, et al. (2011). Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics. Acta Pharmacol Sin 32:1303-8.
2. Cabaleiro T, Roman M, Ochoa D, et al. (2013). Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab Dispos 41:224-9.
3. Dahlof B, Devereux RB, Kjeldsen SE, et al. (2002). Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995-1003.
4. Dai DP, Xu RA, Hu LM, et al. (2013). CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database. Pharmacogenomics J. doi: 10.1038/tpj.2013.2 [Epub ahead of print 12 Feb 2013].
5. DeLozier TC, Lee SC, Coulter SJ, et al. (2005). Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther 315:1085-90.
6. Hiratsuka M. (2012). In vitro assessment of the allelic variants of cytochrome P450. Drug Metab Dispos 27:68-84.
7. Hirota T, Eguchi S, Ieiri I. (2013). Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinet 28:28-37.
8. Hong X, Zhang S, Mao G, et al. (2005). CYP2C9 3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol 61:627-34.
9. Jose R, Chandrasekaran A, Sam SS, et al. (2005). CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fund Clin Pharmacol 19:101-5.
10. Lee CR, Pieper JA, Frye RF, et al. (2003). Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol 43:84-91.
11. Maekawa K, Harakawa N, Sugiyama E, et al. (2009). Substratedependent functional alterations of seven CYP2C9 variants found in Japanese subjects. Drug Metab Dispos 37:1895-903.
12. Rathore SS, Agarwal SK, Pande S, et al. (2010). Frequencies of VKORC1-1639 GA, CYP2C9 2 and CYP2C9 3 genetic variants in the Northern Indian population. Biosci Trends 4:333-7.
13. Schelleman H, Limdi NA, Kimmel SE. (2008). Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics 9:1331-46.
14. Schwarz UI. (2003). Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 33:23-30.
15. Takanashi K, Tainaka H, Kobayashi K, et al. (2000). CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10:95-104.
16. Timmermans PB, Wong PC, Chiu AT, et al. (1993). Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45: 205-51.
17. Van Booven D, Marsh S, McLeod H, et al. (2010). Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genom 20:277-81.
18. Xie HG, Prasad HC, Kim RB, Stein CM. (2002). CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliver Rev 54:1257-70.
19. Yasar U, Forslund-Bergengren C, Tybring G, et al. (2002). Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71:89-98.
20. Yasar U, Tybring G, Hidestrand M, et al. (2001). Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 29:1051-6.
21. Yin T, Maekawa K, Kamide K, et al. (2008). Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 31:1549-57.
22. Zhou SF, Liu JP, Chowbay B. (2009a). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89-295.
23. Zhou SF, Zhou ZW, Huang M. (2010). Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 278: 165-88.
24. Zhou SF, Zhou ZW, Yang LP, Cai JP. (2009b). Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem 16: 3480-675.